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Abstract
Introduction Zellweger spectrum disorders (ZSDs) are caused
by an impairment of peroxisome biogenesis, resulting in multi-
ple metabolic abnormalities. This leads to a range of symptoms,
including hepatic dysfunction and coagulopathy. This study
evaluated the incidence and severity of coagulopathy and the
effect of vitamin K supplementation orally and IV in ZSD.
Methods Data were retrospectively retrieved from themedical
records of 30 ZSD patients to study coagulopathy and the
effect of vitamin K orally on proteins induced by vitamin K
absence (PIVKA-II) levels. Five patients from the cohort with
a prolonged prothrombin time, low factor VII, and elevated
PIVKA-II levels received 10 mg of vitamin K IV. Laboratory
results, including thrombin generation, at baseline and 72 h
after vitamin K administration were examined.
Results In the retrospective cohort, four patients (13.3%) ex-
perienced intracranial bleedings and 14 (46.7%) reported mi-
nor bleeding. No thrombotic events occurred. PIVKA-II
levels decreased 38% after start of vitamin K therapy orally.
In the five patients with a coagulopathy, despite treatment with
oral administration of vitamin K, vitamin K IV caused an
additional decrease (23%) of PIVKA-II levels and increased
thrombin generation.
Conclusion Bleeding complications frequently occur in ZSD
patients due to liver disease and vitamin K deficiency. Vitamin
K deficiency is partly corrected by vitamin K supplementation
orally, and vitamin K administered IV additionally improves
vitamin K status, as shown by further decrease of PIVKA-II
and improved thrombin generation.
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Introduction
Zellweger spectrum disorders (ZSD) are a group of autosomal
recessively inherited disorders with a deficiency of functional
peroxisomes caused by mutations in one of the peroxisome
assembly protein (PEX) genes. (Wanders and Waterham
2006). One of the biochemical consequences of peroxisomal
dysfunction is accumulation of very long-chain fatty acids and
bile acid intermediates [e.g., dihydroxycholestanoic acid
(DHCA) and trihydroxycholestanoic acid (THCA)], contrib-
uting to a variety of symptoms with a spectrum of severity,
including liver disease, developmental delay, and hearing and
vision deficits (Klouwer et al. 2015).
In general, severe liver disease is associated with impair-
ment of coagulation, since the liver synthesizes multiple co-
agulation factors. Deficiencies of fat-soluble vitamins are
common among ZSD patients (Klouwer et al. 2015), and vi-
tamin K deficiency may coexist and partially attribute to the
coagulopathy in these patients. Most ZSD patients therefore
receive supplementation orally of vitamin K and other fat-
soluble vitamins (Berendse et al. 2016). Although ZSD pa-
tients most likely have an increased bleeding diathesis, recent
studies state coagulation rebalance occurs in patients with liv-
er disease, with higher risks of both bleeding and thrombosis
(Lisman and Porte 2011; Magnusson et al. 2016). The pres-
ence of hemorrhages, thrombosis, or effect of vitamin K sup-
plementation orally have not been systematically studied in
ZSD patients. Intravenous (IV) administration of vitamin K
might be more effective than orally, as shown by Pereira et al.
in adults with liver cirrhosis (Pereira et al. 2003). In this study,
subclinical vitamin K deficiency was corrected in 15 of 16
patients receiving 10 mg vitamin K IV compared with three
of 15 receiving oral supplementation. In another study, infants
with hyperbilirubinemia had lower vitamin K concentrations
after oral versus IVadministration of vitamin K, reflecting the
low efficiency of intestinal absorption (Pereira et al. 2005).
We retrospectively evaluated the incidence and severity of
bleeding and thrombotic complications, the pathogenesis of
coagulopathy, and the effect of vitamin K supplementation
orally in ZSD patients. Furthermore, the effect of vitamin K
IV was prospectively studied in five ZSD patients.
Patients and methods
Study design
We retrospectively investigated the incidence and severity of
bleeding and thrombotic complications in a cohort of ZSD
patients at the Academic Medical Center (AMC) in
Amsterdam, The Netherlands. Furthermore, we studied the
pathogenesis of coagulopathy in these patients. We hypothe-
sized that the levels of DHCA and THCA are correlated with
liver disease severity in these patients and consequently to
prothrombin time (PT) and other liver parameters. In addition,
the effect of vitamin K supplementation orally on coagulation
parameters was evaluated. We then prospectively studied the
effect of vitamin K IVon coagulation parameters and throm-
bin generation in five ZSD patients. The Medical Ethics
Committee of the AMC approved this pilot study. Written
informed consent was obtained from all parents of enrolled
patients.
Methods
Retrospective study
The Academic Medical Center in Amsterdam is the expertise
center in The Netherlands for peroxisomal disorders. An
expanding cohort of ZSD patients is followed here and are seen
at the outpatient clinic at least twice a year. Patient data were
retrospectively collected by reviewing the medical records of
30 ZSD patients. All patients with enough data available for
analyses were included, and all received vitamin K supplemen-
tation orally (mixtura phytomenadioni 10 mg/ml base arachis
oil). The starting dose was 1 mg per week and titrated based on
symptoms and laboratory tests, including PT and/or proteins
induced by vitamin K absence (PIVKA-II) levels. Data includ-
ed age, gender, PEX gene mutation, type and severity of bleed-
ing and thrombotic complications, vitamin K supplementation
dose, and the following laboratory parameters: PT, factor V
(FV), factor VII (FVII), aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), DHCA and THCA concentra-
tions, and PIVKA-II levels before and after initiating vitamin
K therapy orally. Bleeding was categorized as major, clinically
relevant, nonmajor, or minor bleeding according to the
Perinatal and Pediatric Subcommittee of the Scientific and
Standardization Committee of the International Society on
Thrombosis and Hemostasis criteria (Mitchell and Male 2011).
Prospective pilot study
For this proof of principle pilot study, five patients with ZSD
aged ≥5 years with a prolonged PT, low FVII, and elevated
PIVKA-II levels were included for the prospective pilot study.
All patients received 10 mg IV in 10 min of phytonadione
(vitamin K1, Konakion MM) dissolved in 0.9% sodium chlo-
ride. Blood samples were obtained by venepuncture before
and 72 h after administration. Blood was collected in plastic
tubes containing trisodium citrate or ethylenediaminetetraac-
etate (EDTA). Coagulation studies included evaluation for PT,
activated partial thromboplastin time (APTT), FV, FVII, factor
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IX (FIX), factor X (FX), PIVKA-II, platelet count, D-dimer,
fibrinogen, and calibrated automated thrombography (CAT).
Coagulation assays
Platelet count and coagulation analyses including PT, APTT,
FV, FVII, FIX, FX, d-dimer, and fibrinogen were determined
in the central laboratory of the hospital. In the retrospective
study, PIVKA-II levels were determined by enzyme-linked
immunosorbent assay (ELISA) (Asserachrom PIVKA-II,
Diagnostica Stago, France). As these kits were discontinued,
in the prospective study, PIVKA-II levels were determined by
ELISAwith a kit from Kamiya Biomedical Company (PIVKA-
II, Japan). In vitro thrombin generation was determined with
CAT, as described (Hemker et al. 2003). Coagulation was trig-
gered by recalcification in the presence of 1 or 5 pM recombi-
nant human tissue factor (Innovin, Siemens Healthcare
Diagnostics, Marburg, Germany), 4 μM phospholipids, and
417 μM fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem,
Bubendorf, Switzerland). Fluorescence was monitored using a
Fluoroskan Ascent fluorometer (ThermoLabsystems, Helsinki,
Finland), and thrombin generation parameters (lag time, peak
height, endogenous thrombin potential, velocity index) were
calculated using Thrombinoscope software (Maastricht,
The Netherlands).
Statistical analysis
In the retrospective study, demographic data were analyzed
using descriptive statistics. Spearman’s correlation coeffi-
cients were calculated to assess the strength of relations be-
tween last measured DHCA or THCA and severity of liver
dysfunction (PT, AST, ALT, FV, FVII). In both studies,
Wilcoxon signed-rank test was used to compare samples be-
fore and after therapy. P ≤ 0.05 was considered statistically
significant. Statistical analysis was performed with SPSS
(IBM SPSS statistics version 22). All collected data are
displayed as graphs using levels before and after vitamin K
therapy [GraphPad Prism (Prism 5 for Mac OS X)].
Results
Retrospective study
Thirty ZSD patients were assessed in the retrospective study.
Mean age was 14.0 ± 8.8 years. Most patients had mutations
in PEX1 (n = 24); patient characteristics are shown in Table 1.
Bleeding and thrombotic complications
Four of the 30 patients (13.3%) developed an intracranial hem-
orrhage, of which three were spontaneous. Characteristics and
laboratory parameters are shown in Table 2. Patient 1 died at the
age of 3 months as result of an intracerebral hemorrhage in the
right frontal lobe with cerebral herniation. PIVKA-II levels
were elevated, and PTwas prolonged. Patient 2 recovered from
a small subdural hemorrhage at the age of 6 years, with elevated
PIVKA-II levels and normal PT and platelets levels. Patient 3
had a traumatic skull fracture with two epidural hemorrhages.
Lab results showed decreased number of platelets, increased
PT, low FV, but normal PIVKA-II. After a few hours, the hem-
orrhages enlarged with signs of herniation, leading to a surgical
decompression procedure. Despite vitamin K therapy orally
and extra vitamin K IV beforehand, bleeding during surgery
was hard to stop. She was treated with tranexamic acid and
received several platelet, erythrocyte, and fresh–frozen plasma
transfusions and recovered after surgery. This patient had nor-
mal PIVKA-II levels in prior years. Patient 4, born after
34 weeks and 2 days, developed grade 1 intraventricular bleed-
ing at the age of 4 days, which increased to grade 3 1 day later.
Conservative therapy led to improvement; no laboratory results
were available for this patient at the time of the bleeding.
Minor bleeding complications, such as nosebleeds, bruises,
and gingiva bleedings, occurred in 14 patients (46.7%). None
of the 30 ZSD patients developed thrombotic events.
Correlation between bile acid intermediates and liver
parameters
Plasma levels of DHCA (r = 0.76, p < 0.001, Fig. 1) and
THCA (r = 0.79, p < 0.001) are significantly correlated with
PT. AST (r = 0.49, p = 0.004), ALT (r = 0.47, p = 0.005), FV
(r = −0.45, p = 0.006), and FVII (r = −0.77, p < 0.001) also
show significant correlations with DHCA. Similar correla-
tions were seen with THCA (data not shown).
Effect of orally administered vitamin K therapy
PIVKA-II levels were measured before and after initiation of
vitamin K orally in 17 patients. The time interval between
measurements varied from 6 to 10 years. Before therapy, all
patients had increased levels of PIVKA-II (Fig. 2a). Median
PIVKA-II level decreased by 38% after start of therapy: to
normal levels in seven patients and to slightly above normal
levels in seven; in three patients (20%), they increased. There
was no significant correlation between the PIVKA-II level and
the vitamin K dose (r = −0.379, p = 0.091) based on data from
14/17 patients).
Prospective pilot study
Effect of intravenously administered vitamin K therapy
Five children (male:female = 1:4), mean age 7.6 years [stan-
dard deviation (SD 1.7)] received vitamin K IV. Four patients
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had PEX1 mutations and one PEX10 mutation. The oral dose
varied between 1 mg administered twice a week and 13 mg/
day. There is a significant correlation between vitamin K dose
orally and PIVKA-II levels in these patients on t = 0 before IV
vitamin K therapy (r = −0.900, p = 0.019). No differences
were seen in global coagulation parameters before and 72 h
after vitamin K. Mean PIVKA-II levels decreased 23%, from
84 to 64.8 mAU/ml (Fig. 2b). After vitamin K IV, thrombin
generation improved, with earlier onset (lag time p = 0.223),
faster rate of thrombin generation (velocity index p = 0.043)
Table 1 Patient characteristics
Variable Reference
values
Results [mean (median;
min, max) ± SD]
Patients with abnormal
value/total (%)
Age in years, n = 30 14.0 (14; 0, 33) ± 8.8
Gender Male, 15
Female, 15
PEX gene, n patients PEX1, 24
PEX6, 1
PEX10, 1
PEX11, 1
PEX26, 1
PIVKA-II in μg/L, before vit K orally <2.5 11.3 (6.6; 2.5, 34.6) ± 10.6 17/17 (100%)
PIVKA-II in μg/L, after vit K orally <2.5 4.1 (2.7; 1.0, 17.4) ± 4.0 11/20 (55%)
PT, in s 9.7–11.6 12.5 (11.9; 10.8, 19.3) ± 1.8 23/30 (77%)
AST in U/L 0–40 52 (46; 0, 178) ± 33.5 17/29 (59%)
ALT in U/L 0–45 41 (32; 16, 125) ± 27.8 9/30 (30%)
Factor V in % 80–140 81 (85; 24, 134) ± 25.5 11/30 (37%)
Factor VII in % 80–140 71 (78; 5, 110) ± 28.9 17/30 (57%)
DHCA in μmol/L 0.0–0.0 2.2 (0.6; 0.0, 17.5) ± 4.0 25/30 (83%)
THCA in μmol/L 0.0–0.1 4.0 (0.3; 0.0, 37.4) ± 8.4 28/30 (93%)
Minor bleeding 14/30 (47%)
Major bleeding 4/30 (13%)
SD standard deviation, PEX peroxisome assembly protein, PIVKA-II proteins induced by vitamin K absence, PT
prothrombin time, AST aspartate aminotransferase, ALT alanine aminotransferase, DHCA dihydroxycholestanoic
acid, THCA trihydroxycholestanoic acid, SD standard deviation
Table 2 Clinical and laboratory parameters in Zellweger spectrum disorders (ZSD) patients with major bleeding complications
Reference values Patient 1 Patient 2 Patient 3 Patient 4
Age at intracranial bleeding 3 months 6 years 7 years 4 days, premature
at 34 weeks
Gender Male Female Female Male
Cause of bleeding Spontaneous Spontaneous Traumatic Spontaneous
Type of bleeding Intracerebral
hemorrhage with
cerebral herniation
Small subdural
hemorrhage
Two epidural
hematomas
Intraventricular
hemorrhage
grade 3
Outcome Died Recovered Surgery, recovered Recovered
Vitamin K supplementation 7 mg/week 7 mg/week 70 mg/week –
PT 9.7–11.6 s 20.2 13.9 16.2 –
PIVKA-II <2.5 μg/L >7360 181 1.7* –
FV 80–140% 114 51 34** –
FVII 80–140% 8 26 35** –
Platelet count 150–450 × 109/L 573 218 91 –
PT prothrombin time, PIVKA-II proteins induced by vitamin K absence, FV factor V, FVII factor VII
*Determined 3 years before the bleeding
**Determined 1 year before the bleeding
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reaching higher peak thrombin values (peak p = 0.043), and a
higher total amount of thrombin formed (endogenous throm-
bin potential p = 0.043) (Fig. 3).
Discussion
This is the first study to investigate the incidence and severity
of bleeding and thrombotic complications in ZSD patients.
Major intracranial bleedings developed in 13.3%, including
one patient born prematurely as a confounding risk factor,
and minor bleedings in almost 50% of patients with a ZSD.
These are most likely underreported due to the study’s retro-
spective design. None of the 30 ZSD patients developed
thrombotic events. However, most patients were young, and
their risk of late-onset thrombosis is unknown. The coagulop-
athy is partly caused by liver disease, probably due to accu-
mulation of toxic bile-acid intermediates (Ferdinandusse et al.
2009). PTwas prolonged in most patients and more prolonged
in patients with higher bile-acid intermediates. Although PT
can be used to investigate a loss of function in the
procoagulant system, it does not predict the risk of bleeding
in patients with liver disease (Lisman and Porte 2011). It is
known that children with liver disease can develop severe
bleeding as well as thrombotic complications (Magnusson
et al. 2016). Reduced synthetic capability of liver cells results
in decreased levels of both procoagulant and anticoagulant
factors. In addition, hyperfibrinolysis may occur in children
with chronic liver disease, especially if the disease is cirrhotic
(El-Sayed et al. 2013). Whether a pediatric patient with liver
disease and loss of reserve capacity develops bleeding or
thrombosis depends on the vascular bed and additional risk
factors in the individual patient (Magnusson et al. 2016). In
children, various diseases are associated with liver failure,
including infections, cholestatic disorders, metabolic disor-
ders, and ischemia due to cardiac diseases. These diseases
are different than those seen in adults and vary with age. In
some diseases, bleedings occur more often, for example, in
biliary atresia or α1-antitrypsin deficiency (Fischler and
Lamireau 2014; Magnusson et al. 2016). Other diseases, such
as cystic fibrosis, are more frequently linked to thrombotic
events (Takemoto 2012). Many metabolic disorders are asso-
ciated with bleeding complications (Croffie et al. 1999;
Fig. 2 a Proteins induced by
vitamin K absence (PIVKA-II) of
17 patients before (dots) and after
(squares) vitamin K therapy ad-
ministered orally. Cutoff range is
<2.5 μg/L. Almost all patients
showed a decreased PIVKA-II
level (p ≤ 0.05). b PIVKA-II
levels before (T = 0) and after
(T = 72 h) vitamin K supplemen-
tation IV. Interrupted lines indi-
cate reference range of 21–56
mAU/ml
Fig. 1 Relationship between last measured dihydroxycholestanoic acid
(DHCA) (x axis, normal range 0.00–0.12 μmol/L) and prothrombin time
(PT) (y axis, normal range 9.7–11.6 s). Trend line indicates a significant
correlation of DHCA and PT (r = 0.76, p < 0.001)
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Preston et al. 2013), and our study extended those findings by
showing that in ZSD patients, bleeding complications are
more prevalent than thromboses.
Impaired hepatic synthesis is not the only cause of coagu-
lopathy in ZSD patients. The many risk factors for developing
vitamin K deficiency, including steatorrhea, poor oral intake
of the vitamin and frequent antibiotic treatment. PIVKA-II is a
functional indicator of vitamin K status. In our retrospective
study, all patients had increased levels in the absence of vita-
min K therapy, consistent with vitamin K deficiency. Vitamin
K supplementation orally decreased PIVKA-II levels by 38%
but did not normalize them in most patients. The three patients
with a rise in PIVKA-II levels after supplementation orally
also had a decrease in FV and an increase in PT. This could
be explained by further progression of the disease, since the
time interval between both measurements varied from 6 to
10 years.
In the prospective study, we aimed to improve one of the
causes of coagulopathy in ZSD patients, i.e., vitamin K status,
by giving vitamin K IV. This had no effect on global coagu-
lation parameters but did lower PIVKA-II levels by another
23%. This decrease was most apparent in patients with the
highest levels before IV therapy. In one patient, PIVKA-II
increased from 27 to 36 mAU/ml but remained within the
normal range of 21–56 mAU/ml. Furthermore, thrombin gen-
eration was significantly improved, although it remains to be
determined whether regular vitamin K supplementation IV
will diminish bleeding complications in ZSD patients.
Nevertheless, in clinical situations, including during bleeding
episodes or before dental or surgical procedures, it seems to
have an additional positive effect on coagulation. As ZSD
patients have a high risk of bleeding, consultation with a he-
matologist before a surgical procedure or after trauma is im-
portant to discuss patient coagulation status and management.
There is insufficient evidence, however, to give vitamin K IV
on a regular basis, since it is a real burden for those children.
However, it may be useful to measure PIVKA-II more often,
as supportive care with vitamin K therapy orally could be
improved or in some cases boosted with IV administration.
More comprehensive research is indicated in larger pop-
ulations to examine the clinical relevance of our labora-
tory findings.
In conclusion, both liver disease and vitamin K deficiency
contribute to coagulopathy in ZSD patients, which particularly
manifests as bleeding complications. Vitamin K deficiency is
partly corrected by administering vitamin K therapy orally,
and added IV administration improves vitamin K status, as
shown by further decrease of PIVKA-II and improved throm-
bin generation.
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Fig. 3 Thrombin generation
analysis of Zellweger spectrum
disorders (ZSD) patients.
Thrombin generation was initiat-
ed with a1 pM or b 5 pM tissue
factor. Thrombin generation was
averaged for five patients before
and after 72 h of vitamin K ther-
apy IV
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